Correction to: Real‑World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review
Saved in:
| Main Authors: | Andrew M. Blumenfeld, Laszlo Mechtler, Lisa Cook, Christopher Rhyne, Brian Jenkins, Olivia Hughes, Brett Dabruzzo, Aubrey Manack Adams, Merle Diamond |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2024-12-01
|
| Series: | Pain and Therapy |
| Online Access: | https://doi.org/10.1007/s40122-024-00692-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of onabotulinumtoxinA treatment in episodic migraine
by: Jasem Al-Hashel, et al.
Published: (2025-01-01) -
Comparing eptinezumab with onabotulinumtoxinA in the treatment of chronic migraine: a real-world evidence study
by: Damiana Scuteri, et al.
Published: (2025-07-01) -
Patient Satisfaction with Aesthetic Outcomes Following OnabotulinumtoxinA Treatment for Chronic Migraine: A Cross-Sectional Study
by: Magdalena Boczarska-Jedynak, et al.
Published: (2025-06-01) -
Intradetrusor OnabotulinumtoxinA outcomes for overactive bladder in older adults
by: Rachel Stading, et al.
Published: (2024-12-01) -
OnabotulinumtoxinA for trigeminal neuralgia: a review of the available data
by: Pedro A. Kowacs, et al.
Published: (2015-01-01)